We are live on ! Find out more
NTRP icon

Neurotrope
NTRP

Delisted

NTRP was delisted on the 1st of December, 2020.

27 hedge funds and large institutions have $9M invested in Neurotrope in 2017 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

235% more capital inflows, than outflows

Capital inflows: $7.23M | Capital outflows: $2.16M

220% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 5

82% more call options, than puts

Call options by funds: $837K | Put options by funds: $460K

69% more funds holding

Funds holding: 16 → 27 (+11)

6.73% more ownership

Funds ownership: 5.46% → 12.19% (+6.7%)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
27
Holders Change
+11
Holders Change %
+68.75%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
16
Increased
7
Reduced
2
Closed
5
Calls
$837​K
Puts
$460​K
Net Calls
+$377​K
Net Calls Change
+$377​K

NTRP Hedge Fund Activity: Q2 2017 in Review

27 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Neurotrope (NTRP) for Q2 2017, worth a combined $9M — up 16% from $7.78M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new NTRP positions and 5 closed out — a net gain of 11 holders — while 7 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $2.08M. The largest seller was Knoll Capital Management, exiting entirely with an estimated $867K sold.

  • 27 institutional investors held Neurotrope (NTRP) as of Q2 2017, up from 16 in Q1 2017.
  • Funds reported $9M of Neurotrope stock for Q2 2017, up 16% quarter-over-quarter.
  • 16 funds opened new Neurotrope positions in Q2 2017 and 5 closed out, a net change of +11 holders.
  • The largest Neurotrope buyer in Q2 2017 was Vanguard Group, an estimated $2.08M added.
  • The largest Neurotrope seller in Q2 2017 was Knoll Capital Management, an estimated $867K sold.

Based on aggregated 13F filings for Q2 2017.